TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our actions. We are dedicated to improving the oncology experience and have a passionate commitment to unconditional care, which puts science for patients first. At TESARO, there is nothing conditional about who we are or what we do.
Our singular oncology approach enables our associates to focus their energy and resources on delivering transformative therapeutic experiences to people living with cancer, their care partners, and to the healthcare providers who treat them. But we don’t do this alone. Collaborative relationships are vital to the fulfillment of our mission and to being a trusted partner in the community.
Until cancer is cured, we will continue doing what is right for the people in the oncology community.
There is nothing conditional about what we do.
Or who we are.
Or how we treat you.
We do what’s right.
We put science for patients first, disrupting the model to go beyond the concepts of conventional care.
We don’t treat a condition.
We treat people & partners.
We care to change the future.
On January 22, 2019, TESARO was acquired by GSK. This new partnership enables us to accelerate our vision of bringing transformative therapies to people living with cancer.